PEP08 / PharmaEngine, XtalPi - LARVOL DELTA

A Study of PEP08 in Patients With MTAP-Del Advanced or Metastatic Solid Tumors (clinicaltrials.gov) - P1 | N=40 | Recruiting | Sponsor: PharmaEngine | Not yet recruiting ➔ Recruiting

Enrollment open • First-in-human • Monotherapy • Oncology • Solid Tumor • MTAP

XtalPi AI Drug Discovery Collaboration Reaches Milestone as PharmaEngine's Novel PRMT5 Inhibitor PEP08 Receives Clinical Trial Approvals (PRNewswire) - "XtalPi Inc...has announced that PEP08, a next-generation PRMT5 inhibitor candidate developed through its AI drug discovery collaboration with PharmaEngine, Inc...has received regulatory clearances to initiate Phase 1 clinical trials in solid tumors. Approvals include Australia's Human Research Ethics Committee (HREC), recognized by the Australian Therapeutic Goods Administration (TGA), and the food and drug authority of the Taiwan region (TFDA). This milestone triggered a payment to XtalPi under the partnership agreement."

New P1 trial • Solid Tumor